Free Trial

Tempus AI (TEM) to Release Earnings on Monday

Tempus AI logo with Medical background
Remove Ads

Tempus AI (NASDAQ:TEM - Get Free Report) will likely be announcing its Q4 2024 earnings results after the market closes on Monday, February 24th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $202.80 million for the quarter. Tempus AI has set its FY 2025 guidance at EPS.Persons that are interested in participating in the company's earnings conference call can do so using this link.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.18). On average, analysts expect Tempus AI to post $-6 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tempus AI Trading Up 2.2 %

TEM traded up $1.48 on Monday, hitting $69.57. 19,810,150 shares of the stock traded hands, compared to its average volume of 14,555,437. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI has a 52 week low of $22.89 and a 52 week high of $91.45. The business has a fifty day moving average price of $50.88 and a two-hundred day moving average price of $52.03.

Analyst Ratings Changes

TEM has been the subject of a number of recent research reports. Stifel Nicolaus cut shares of Tempus AI from a "buy" rating to a "hold" rating and increased their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. TD Cowen reiterated a "buy" rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Loop Capital lowered their price objective on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a research report on Tuesday, January 14th. Wolfe Research initiated coverage on Tempus AI in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price for the company. Finally, Guggenheim started coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a "buy" rating and a $74.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.55.

Remove Ads

View Our Latest Analysis on Tempus AI

Insider Buying and Selling at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 187,655 shares of Tempus AI stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the transaction, the chief executive officer now owns 9,557,283 shares in the company, valued at $358,780,403.82. The trade was a 1.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total value of $16,999,610.00. Following the sale, the insider now directly owns 16,164,449 shares of the company's stock, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,583,467 shares of company stock valued at $130,542,311.

About Tempus AI

(Get Free Report)

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Recommended Stories

Should You Invest $1,000 in Tempus AI Right Now?

Before you consider Tempus AI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.

While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Trump Tariffs Tumble the Stock Market—Here’s How to Protect Your Money
Donald Trump Owns These 7 Stocks, Should You?
 5 Stocks to BUY NOW in April 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads